ART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. CURRENT CORRESPONDENCE ADDRESS (Note: Legility quark-up with any corrections or use Block I) 06/10/2004 005487 7590 Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FRE address above, or being facsimile transmitted to hip USPTO, on the date indicated below. ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. **ROUTE 202-206** MAIL CODE: D303A (Depositor's anme) Stein BRIDGEWATER, NJ 08807 (Signature) (Date) FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. FILING DATE APPLICATION NO. HMR 204LLIS-NP1 4289 01/16/2001 Kurt M. Kesseler 09/760.590 TITLE OF INVENTION: ETHANOL SOLVATE OF (3-E12.2. (2-CHLOROPHENYL)-5-2-DIHYDROXY-2-JAR-J3S-FYDBOXY-1-M. ETHYL) PIPERIDINYL) -4H-1-BENZOPYRAN-4-ONE TOTAL FEE(S) DUE DATE DUE PUBLICATION FEE ISSUE FEE APPLN. TYPE SMALL ENTITY 09/10/2004 \$1630 \$1330 \$300 NO nonprovisional CLASS-SUBCLASS ART UNIT EXAMINER 514-320000 1625 CHANG, CELIA C Lawrence L. Martin Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, (2) the name of a single O Charge of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. firm (having as a member a registered attorney or Balaram Gupta agent) and the names of up to 2 registered patent O "Fee Address" indication (or "Pee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. attorneys or agents. If no name is listed, no name Joseph Kirk will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filling an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE Frankfurt, Fed. Rep. Germany Aventis Pharma Deutschland GmbH Please check the appropriate assignee category or categories (will not be printed on the patent); individual Corporation or other private group entity 4b. Payment of Fee(s): 4a. The following fee(s) are enclosed: ☑ Issue Fee ☐ A check in the amount of the fee(s) is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached. Drublication Fee Advance Order - # of Copies Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. (Date) (Jay No 46,902 (Authorized Signature) 09/08/2004 AWDNDAF2 00000073 181982 09760590 9/7/04 1330.00 DA 01 FC:1501

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant, a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, perparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of sime you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petern and Trudemark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

300.00 DA 02 FC:1504 03 FC:8001 12.00 DA

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 11/03) Approved for use through 04/30/2004.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

SEP 0 7 2004 5

FAX TRANSMITTAL TO THE UNITED STATES PATENT OFFICE

	•				
Applicants Docket Number: USHMR2041US NP1 Applicants: Kurt M. Kesseler Serial No. 09/760,590 Filing Date: January 16, 2001 Title of Invention: Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-methyl)piperidinyl]-4H-1-benzopyran-4-one		CERTIFICATE OF TRANSMISSION I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, Issue Fee, at 703-747-4000, on Date of Deposit September 7, 2004 Printed Name of Person Signing Certificate Bonnie Stein Signature Brance, Scheme 2 Attorney: Lawrence L. Marten Group Art Unit: 1625 Examiner: Celia C. Chang 5,7-dihydroxy-8-[4R-(3S-hydroxy-1-			
memit/hibertemitil.att.t.nemobitem.a.one					
TO:	Mail Stop Issue Fee Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450				
Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,					
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit					
account (18-1982) in the name of Aventis Pharmaceuticals Inc.					
	Amendment, 37 CFR		Гее Тта	nsmittal	
	Charge deposit account, in duplicate		Petition	under 37 CFR	
	Extension of Time Petition		Other _		
\boxtimes	Issue Fee Transmittal & Advance Order - 1 pg.		Other _	<u> </u>	
	Maintenance Fee Transmittal				
Rece	ipt Confirmed:				
Signed		Date	Dated		

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmacouricals Inc. template (March 2001)